TAIPEI, Taiwan I March 26, 2025 I AnHorn Medicines, a pioneering AI-driven new drug discovery company, is pleased to announce that, AH-001, a first-in-class ...

Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further ...

EMERYVILLE, CA, USA I March 26, 2025 I Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization (CRDMO) with a next ...

Agreement enables olezarsen to reach people living with conditions associated with elevated triglycerides across the world – ...

Bayer obtains exclusive worldwide license for MTA-cooperative PRMT5 inhibitor for selective targeting of MTAP-deleted tumors ...

PARIS, France I March 26, 2025 I The US Food and Drug Administration has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention ...

CHENGDU, China I March 25, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical ...

Systemic administration of Olvi-Vec in the initial dose escalation cohorts achieved a 71% disease control rate (5/7) with two partial responders. All ...

PLANO, TX & BALTIMORE, MD, USA I March 25, 2025 I Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from ...

PARIS, France I March 25, 2025 I The US Food and Drug Administration (FDA) is evaluating under priority review the regulatory submission of tolebrutinib to ...

GUANGDONG, China and BAGSVAERD, Denmark I March 24, 2025 IThe United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S (Novo Nordisk) ...

NEW YORK, NY, USA I March 24, 2025 I On March 17, 2025, US time, the world's first acute myocardial infarction (AMI) antibody drug, SGC001, developed by ...